Literature DB >> 2893761

Double blind comparison of the effects of cimetidine, ranitidine, famotidine, and placebo on intragastric acidity in 30 normal volunteers.

H S Merki1, L Witzel, R P Walt, J Neumann, E Scheurle, A Mappes, H Krammisch, J Heim, D Kaufmann, J Roehmel.   

Abstract

Continuous measurement of 24 hour intragastric acidity was carried out in 30 normal volunteers during treatment with placebo, cimetidine 800 mg, ranitidine 300 mg, and famotidine 40 mg in a double blind study. Medication was taken after the evening meal (post cenam nocte, PCN). Median 24 hour acidity decreased with all H2-receptor antagonists from 25.1 mmol/l on placebo to 10 mmol/l (-60.1%) during cimetidine, to 3.2 mmol/l (-87.25%) during ranitidine and to 2.5 mmol/l (-90.0%) during famotidine treatment (p less than 0.0005). All drugs significantly inhibited night time acidity but only famotidine decreased acidity during the late morning compared with placebo. Significantly greater acid reduction was seen with famotidine and ranitidine compared with cimetidine but no difference was found between famotidine and ranitidine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2893761      PMCID: PMC1433250          DOI: 10.1136/gut.29.1.81

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  [H2 receptor antagonists and intragastric acidity].

Authors:  H G Dammann; T A Walter; P Müller; B Simon
Journal:  Dtsch Med Wochenschr       Date:  1984-11-16       Impact factor: 0.628

2.  Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer.

Authors:  T Gledhill; O M Howard; M Buck; A Paul; R H Hunt
Journal:  Gut       Date:  1983-10       Impact factor: 23.059

3.  Gastrointestinal angiodysplasia associated with aortic valve disease: part of a spectrum of angiodysplasia of the gut.

Authors:  G A Weaver; H D Alpern; J S Davis; W H Ramsey; M Reichelderfer
Journal:  Gastroenterology       Date:  1979-07       Impact factor: 22.682

4.  Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.

Authors:  B K Sharma; R P Walt; R E Pounder; M D Gomes; E C Wood; L H Logan
Journal:  Gut       Date:  1984-09       Impact factor: 23.059

5.  24-hour control of intragastric acidity by cimetidine in duodenal-ulcer patients.

Authors:  R E Pounder; J G Williams; G J Milton-Thompson; J J Misiewicz
Journal:  Lancet       Date:  1975-11-29       Impact factor: 79.321

6.  Cimetidine or vagotomy? Comparison of the effects of proximal gastric vagotomy, cimetidine and placebo on nocturnal intragastric acidity and acid secretion in patients with cimetidine resistant duodenal ulcer.

Authors:  T Gledhill; M Buck; A Paul; R H Hunt
Journal:  Br J Surg       Date:  1983-12       Impact factor: 6.939

7.  Single dose treatment with H2 receptor antagonists: is bedtime administration too late?

Authors:  H Merki; L Witzel; K Harre; E Scheurle; J Neumann; J Röhmel
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

8.  Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage.

Authors:  P J Prichard; N D Yeomans; G W Mihaly; D B Jones; P J Buckle; R A Smallwood; W J Louis
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

9.  Comparison of the effects of ranitidine, cimetidine and placebo on the 24 hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer.

Authors:  R P Walt; P J Male; J Rawlings; R H Hunt; G J Milton-Thompson; J J Misiewicz
Journal:  Gut       Date:  1981-01       Impact factor: 23.059

10.  Effect of daily oral omeprazole on 24 hour intragastric acidity.

Authors:  R P Walt; M D Gomes; E C Wood; L H Logan; R E Pounder
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-02
View more
  10 in total

1.  Chronic omeprazole treatment increases duodenal susceptibility to ethanol injury in rats.

Authors:  R A Erickson; S Bezabah; G Jonas; E Lifrak; A S Tarnawski
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

2.  A comparative study of once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating duodenal ulcers.

Authors:  M Okada; M Arita; M Iida; T Yao; T Sakurai; K Hoshiko; K Maeda; Y Okada; K Sakamoto
Journal:  Gastroenterol Jpn       Date:  1992-04

Review 3.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 4.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

5.  Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer.

Authors:  V Savarino; G S Mela; P Zentilin; G Bonifacino; M Moretti; F Valle; G Celle
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

Review 6.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 7.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

8.  Comparison of low-dose antacids, cimetidine, and placebo on 24-hour intragastric acidity in healthy volunteers.

Authors:  R Weberg; A Berstad; M Osnes
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

Review 9.  Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers.

Authors:  M Deakin; J G Williams
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

10.  Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy.

Authors:  Miho Yamasaki; Sachiyo Funakoshi; Shohei Matsuda; Tomoko Imazu; Yoshiaki Takeda; Teruo Murakami; Yorinobu Maeda
Journal:  Eur J Clin Pharmacol       Date:  2014-05-13       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.